Novo Nordisk A/S (NONOF)
Data as of September 4, 2026 · Biotechnology
Stockbruh grade: Mixed 2/5 metrics rated Sunny
What does Novo Nordisk A/S do?
Novo Nordisk A/S, a global healthcare company 🌍, researches, develops, manufactures, and markets pharmaceutical products 🧪. They focus on diabetes and obesity care, offering insulins and other essentials 🩺. They also provide solutions for haemophilia and growth disorders 🔬. Based in Bagsvaerd, Denmark 🇩🇰, Novo Nordisk is committed to improving lives and finding innovative ways to tackle chronic diseases 🚀..
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ⛈️ Weak | 5-year price performance |
| Profitability | ☀️ Strong | Net margin & return on equity |
| Growth | ☀️ Strong | Revenue & earnings trend |
| Earnings | ⛅ Moderate | EPS vs analyst expectations |
| Cash & Debt | ⛈️ Weak | Balance sheet strength |
| Price | $46.50 | Market Cap | — |
| Exchange | Other OTC | | |
Plain-English Analysis
What's it worth?
Returns have been below average recently — worth reviewing valuation carefully before investing. Sign up free to see the full Stockbruh valuation breakdown.
How the business works
Novo Nordisk A/S, a global healthcare company 🌍, researches, develops, manufactures, and markets pharmaceutical products 🧪. They focus on diabetes and obesity care, offering insulins and other essentials 🩺. Sign up free for competitor and revenue breakdown ↗
Are they building the future?
Revenue and earnings are trending upward — Novo Nordisk A/S appears to be growing. Sign up free for the full growth analysis including year-over-year comparisons and R&D investment data.
What's ahead?
Earnings are mixed. Sign up free for the full earnings picture including EPS history and analyst forecasts.